Evidence map›Paper›PMID 35607844›Full record

ArticleMicrobiology and immunology2022

Prevalence of saliva immunoglobulin A antibodies reactive with severe acute respiratory syndrome coronavirus 2 among Japanese people unexposed to the virus.

Keiichi Tsukinoki, Tetsuro Yamamoto, Jiro Saito, Wakako Sakaguchi, Keiichiro Iguchi, Yoshinori Inoue, Shigeru Ishii, Chikatoshi Sato, Mina Yokoyama, Yuki Shiraishi and 10 more

Open access · greenAbstract read
In one paragraph

Article in Microbiology and immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Salivary polyreactive antibodies andThe European respiratory journal · 2024
    Article
  2. Article
  3. SIgA in various pulmonary diseases.European journal of medical research · 2023
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Keiichi TsukinokiDepartment of Environmental Pathology, Graduate School of Dentistry, Kanagawa Dental University, Kanagawa, Japan.ORCID http://orcid.org/0000-0002-0005-2615
Tetsuro YamamotoEPS Research Center, EPS Holdings, Inc., Tokyo, Japan.
Jiro SaitoMedical Station Clinic, Tokyo, Japan.
Wakako SakaguchiDepartment of Environmental Pathology, Graduate School of Dentistry, Kanagawa Dental University, Kanagawa, Japan.ORCID http://orcid.org/0000-0002-6365-0209
Keiichiro IguchiDepartment of Orthodontics, Kanagawa Dental University, Kanagawa, Japan.
Yoshinori InoueDepartment of Pediatric Dentistry, Kanagawa Dental University, Kanagawa, Japan.
Shigeru IshiiDepartment of Advanced Oral Surgery, KDU Yokohama Clinic, Kanagawa, Japan.ORCID http://orcid.org/0000-0001-9606-1083
Chikatoshi SatoDepartment of Orthodontics, KDU Yokohama Clinic, Kanagawa, Japan.
Mina YokoyamaDepartment of Pediatric Dentistry, Kanagawa Dental University, Kanagawa, Japan.
Yuki ShiraishiEPS Research Center, EPS Holdings, Inc., Tokyo, Japan.
Noriaki KatoEPS Research Center, EPS Holdings, Inc., Tokyo, Japan.ORCID http://orcid.org/0000-0003-1440-5490
Hiroyasu ShimadaEPS Research Center, EPS Holdings, Inc., Tokyo, Japan.
Akio MakabeSites Support Section, Foods Department, EP Mediate Co., Ltd., Tokyo, Japan.
Akihiro SaitoSites Support Section, Foods Department, EP Mediate Co., Ltd., Tokyo, Japan.
Masanori TanjiEPS Research Center, EPS Holdings, Inc., Tokyo, Japan.
Isao NagaokaDepartment of Host Defense and Biochemical Research, Faculty of Health Science, Juntendo University, Tokyo, Japan.
Juri SarutaDepartment of Education Planning, Kanagawa Dental University, Kanagawa, Japan.
Tetsutaro YamaguchiDepartment of Orthodontics, Kanagawa Dental University, Kanagawa, Japan.ORCID http://orcid.org/0000-0001-9806-7163
Shigenari KimotoDepartment of Pediatric Dentistry, Kanagawa Dental University, Kanagawa, Japan.
Hideyo YamaguchiEPS Research Center, EPS Holdings, Inc., Tokyo, Japan.
Kanagawa Dental University · JPJuntendo University · JPTeikyo University · JP

Funding

EPS Holdings, Inc., Japan
6 · The paper itself

Abstract

While the COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a threat to public health as the number of cases and COVID-19-related deaths are increasing worldwide, the incidence of the virus infection is extremely low in Japan compared with many other countries. To explain this uncommon phenomenon, we investigated the prevalence of naturally occurring ("natural") antibodies, focusing on those of the secretory immunoglobulin A (sIgA) form, reactive with SARS-CoV-2 among Japanese people. One hundred and eighty healthy Japanese volunteers of a wide range of age who had been considered to be unexposed to SARS-CoV-2 participated in this study. Saliva samples and blood samples were collected from all of the 180 participants and 139 adults (aged ≥ 20 years) included therein, respectively. The determination of saliva IgA antibodies, mostly comprising sIgA antibodies, as well as serum IgA and immunoglobulin G antibodies, reactive with the receptor binding domain of the SARS-CoV-2 spike-1 subunit proteins was conducted using an enzyme-linked immunosorbent assay. The major findings were that 52.78% (95% confidence interval, 45.21%-60.25%) of the individuals who had not been exposed to SARS-CoV-2 were positive for saliva IgA antibodies with a wide range of levels between 0.002 and 3.272 ng/mL, and that there may be a negative trend in positivity for the antibodies according to age. As we had expected, a frequent occurrence of assumable "natural" sIgA antibodies reactive with SARS-CoV-2 among the studied Japanese participant population was observed.

Indexed as

COVID-19SARS-CoV-2AdultAntibodies, ViralHumansImmunoglobulin AImmunoglobulin A, SecretoryImmunoglobulin MJapanPandemicsPrevalenceSalivaAntibodies, ViralImmunoglobulin AImmunoglobulin A, SecretoryImmunoglobulin MCOVID-19Japanese peoplesaliva IgASARS-CoV-2secretory IgAseroprevalence

Identifiers

PMID35607844
PMCPMC9347685
OpenAlexW4282944410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.